Meropenem Dr. Friedrich Eberth (Meropenem Trihydrate)

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

• Complicated intra‑abdominal infections: provides rapid bacterial clearance and reduces infection‑related mortality.
• Complicated urinary tract infections: eradicates resistant Gram‑negative pathogens causing severe UTIs.
• Hospital‑acquired pneumonia: targets multidrug‑resistant organisms in ventilated patients.
• Severe sepsis and septic shock: delivers high‑dose bactericidal activity to control systemic infection.
• Bacterial meningitis: penetrates the cerebrospinal fluid to treat acute meningitis caused by susceptible strains.

• Meropenem binds to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic lysis and bacterial death. The molecule is resistant to most β‑lactamases, allowing activity against a broad range of Gram‑positive and Gram‑negative organisms, including many multidrug‑resistant strains.

Adverse reactions may occur with any antimicrobial therapy and should be monitored during treatment.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limiting.
• Rash: erythematous skin eruption.
• Headache: transient and usually resolves after therapy.
• Elevated liver enzymes: transient increase in ALT/AST.
• Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or CNS disorders.
• Clostridioides difficile colitis: severe diarrhea due to gut flora disruption.
• Anaphylaxis: acute hypersensitivity reaction requiring emergency care.
• Severe hypersensitivity: including Stevens‑Johnson syndrome.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Thrombocytopenia: low platelet counts requiring monitoring.

Careful assessment and monitoring are essential when using meropenem in high‑risk patients.

• Renal function assessment: adjust dosing in patients with impaired clearance.
• Seizure risk evaluation: avoid in patients with a history of epilepsy or CNS disorders.
• Hypersensitivity screening: discontinue if signs of severe allergic reaction appear.
• Concomitant nephrotoxic drugs: monitor renal parameters closely.
• Pregnancy and lactation: use only if the potential benefit outweighs the risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

• Valproic acid: meropenem reduces serum valproate levels, increasing seizure risk.
• Other carbapenems: combined use may increase neurotoxicity.
• Nephrotoxic agents (e.g., aminoglycosides): additive renal impairment.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR for potential anticoagulant effect changes.
• Diuretics: may affect renal clearance of meropenem.
• Other antibiotics (e.g., linezolid): assess for antagonistic effects on bacterial killing.